H.C. Wainwright raised the firm’s price target on Kymera Therapeutics (KYMR) to $84 from $70 and keeps a Buy rating on the shares. The firm remains “encouraged” on Kymera’s upcoming BroADen Phase 1b readout, saying it represents the first patient-level test of KT-621’s ability to replicate dupilumab-like pathway control in an oral format.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $70 from $60 at Barclays
- Kymera Therapeutics Reports Q3 2025 Financial Results
- Kymera Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
- Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges
- Kymera Therapeutics price target raised to $73 from $70 at Morgan Stanley